Genmab often talks about its “knock-your-socks-off” antibodies — and now the term is getting its own logo and corporate campaign.

The teal and purple logo for the acronym KYSO — Genmab pronounces it “ky-so” — debuts on Wednesday and comes on the heels of Genmab’s newly announced 2030 vision. That aspiration aims to expand Genmab’s drug development beyond oncology to include other serious diseases, while also doubling down on its own drug development.

Unlock this story instantly and join 148,500+ biopharma pros reading Endpoints daily — and it's free.

Pre-pandemic, the life sciences industry had settled into a pattern. The average drug took 12 years and $2.9 billion to bring to market, and it was an acceptable mode of operations, according to Nimita Limaye, Research Vice President for Life Sciences R&D Strategy and Technology at IDC.

COVID-19 changed that, and served as a proof-of-concept for how technology can truly help life sciences companies succeed and grow, Limaye said. She recently spoke about industry trends at Egnyte’s Life Sciences Summit 2022. You should watch the entire session, free and on-demand, but here’s a brief recap of why she’s urging life sciences companies to embrace digital transformation.

James Sabry’s BD team at Roche has a long track record in hunting the globe for new biotech deals. But they’ve never journeyed into China before to ink a worldwide development and commercialization pact with a China-based biotech on an experimental med.

As Max Gelman reported yesterday, Roche fronted a new alliance with China’s Jemincare with $60 million in cash and $590 million in milestones for worldwide commercial rights to an oral androgen receptor degrader. The deal itself is fairly typical of an early-stage alliance around a promising treatment. The Shanghai-based biotech is largely unknown outside China, but this is a classic high-risk, modest upfront pact that Roche routinely inks.

Unlock this article along with other benefits by subscribing to one of our paid plans.

Roche’s Genentech is going high style next month for New York Fashion Week. The pharma is hosting its first-ever runway fashion show to raise disability visibility, featuring models from the spinal muscular atrophy (SMA) community.

“Double Take” will be held Sept. 8, the day before the official New York event begins, with models walking and rolling across the stage wearing stylish and functional adaptive clothing. Eleven people living with SMA and four advocates will show off the custom fashions created by Open Style Lab, a Brooklyn nonprofit and accessible clothing design collaborative.

Unlock this story instantly and join 148,500+ biopharma pros reading Endpoints daily — and it's free.

It’s been just two days since Endo International filed for bankruptcy in an attempt to dig itself out of thousands of opioid lawsuits. Now one of its top sellers is in trouble.

A federal appeals court on Thursday affirmed a Delaware judge’s decision that Eagle Pharmaceuticals’ generic version of Endo’s vasopressin injection Vasostrict does not infringe on the company’s patents. Eagle’s version won approval back in December, and already, the generic and others like it have driven down Vasostrict sales.

Martin Landray knows what controversy in clinical drug development feels like, from first-hand experience.

Landray was the chief architect of RECOVERY, a study that pitted a variety of drugs against Covid-19. And he offered some landmark data that would help push dexamethasone out into broader use as a cheap treatment, while helping ice hydroxy’s reputation as a clear misfire.

“Lots of people told us we shouldn’t use it,” Landray says about dexamethasone and Covid-19. “It was dangerous. We shouldn’t even do a trial. They also cared about hydroxychloroquine and lots of people said we shouldn’t do a trial because it must be used. I’ve got the letters from both sets of people.”

Unlock this article along with other benefits by subscribing to one of our paid plans.

After a nearly 365-day delay, Axsome Therapeutics has secured its first drug approval with an FDA green light for Auvelity as a treatment for adults with major depressive disorder.

The biotech is keeping shy on the pricing for now and, on an investor call, CEO Herriot Tabuteau attributed the FDA’s yearlong delay mainly to the Covid-19 pandemic. The rapid-acting NMDA receptor antagonist is not a scheduled drug under the DEA, the CEO confirmed on the call.

Unlock this story instantly and join 148,500+ biopharma pros reading Endpoints daily — and it's free.

A year ago, miR Scientific lit up La Fortaleza, the governor’s mansion in Puerto Rico, and other landmarks on the island in the color blue for Prostate Cancer Awareness Month. Next month, the company is taking the campaign international as it launches its prostate cancer diagnostic test.

miR is coordinating an effort to light up dozens of landmarks in New York, New Jersey, Chicago and Puerto Rico on Sept. 1 as part of its “Can Do Blue” campaign. It’s also hoping to spread the word in Canada, Israel, Japan, Singapore and other markets.

Novo Nordisk debuted its first diversity and inclusion report in North America this week laying out its commitments — and progress — for employees, patients and external audiences.

The highlights include more inclusive parental policies, nine employee resource groups — including a new AllAbility disability awareness group — and specialized programs such as its weekly Diversity, Equity, Inclusion and Belonging (DEI&B) open forum discussions.

Unlock this story instantly and join 148,500+ biopharma pros reading Endpoints daily — and it's free.

José Romero is a Latino HIV activist in Durham, North Carolina — and one of the stars of Gilead Sciences’ docuseries about the impact of HIV in the South.

The six-part “Blind Angels” series initially aired on CNN over the past few months with individual episodes now being submitted and screened at film festivals around the country. Romero’s episode, for instance, was screened at the OutSouth Queer Film Festival in Raleigh-Durham last weekend. Romero spoke at the festival and to a “standing room only” audience, a Gilead spokesperson said.

Unlock this story instantly and join 148,500+ biopharma pros reading Endpoints daily — and it's free.

Bioscience & Technology Business Center The University of Kansas Lawrence, Kansas

If you're already an Endpoints subscriber, enter your email below for a magic link that lets you log in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours.

We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 2 PM ET

ENDPOINTS MARKETING RX Tue at 2 PM ET

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET